Growth Hormone Secretagogue Receptor Type 1 – Pipeline Review, H1 2020

Global Markets Direct’s, ‘Growth Hormone Secretagogue Receptor Type 1 (GH Releasing Peptide Receptor or Ghrelin Receptor or GHSR) – Pipeline Review, H1 2020’, provides in depth analysis on Growth Hormone Secretagogue Receptor Type 1 (GH Releasing Peptide Receptor or Ghrelin Receptor or GHSR) targeted pipeline therapeutics. The report provides comprehensive information complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Growth Hormone Secretagogue Receptor Type 1 (GH Releasing Peptide Receptor or Ghrelin Receptor or GHSR) targeted therapeutics development and features dormant and discontinued projects. The report analyses the pipeline products from therapy areas Oncology, Central Nervous System, Toxicology, Cardiovascular, Genetic Disorders, Hormonal Disorders, Metabolic Disorders, Gastrointestinal, Genito Urinary System And Sex Hormones, Infectious Disease, Musculoskeletal Disorders and Women's Healthunder development targeting Growth Hormone Secretagogue Receptor Type 1 (GH Releasing Peptide Receptor or Ghrelin Receptor or GHSR).

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

*Updated report will be delivered in 48 hours of order confirmation.

Scope

– The report provides a snapshot of the global therapeutic landscape for Growth Hormone Secretagogue Receptor Type 1 (GH Releasing Peptide Receptor or Ghrelin Receptor or GHSR)

– The report reviews Growth Hormone Secretagogue Receptor Type 1 (GH Releasing Peptide Receptor or Ghrelin Receptor or GHSR) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

– The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

– The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

– The report reviews key players involved in Growth Hormone Secretagogue Receptor Type 1 (GH Releasing Peptide Receptor or Ghrelin Receptor or GHSR) targeted therapeutics and enlists all their major and minor projects

– The report assesses Growth Hormone Secretagogue Receptor Type 1 (GH Releasing Peptide Receptor or Ghrelin Receptor or GHSR) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

– The report summarizes all the dormant and discontinued pipeline projects

– The report reviews latest news and deals related to Growth Hormone Secretagogue Receptor Type 1 (GH Releasing Peptide Receptor or Ghrelin Receptor or GHSR) targeted therapeutics

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand the targeted therapy areas and indications for Growth Hormone Secretagogue Receptor Type 1 (GH Releasing Peptide Receptor or Ghrelin Receptor or GHSR)

- Identify the use of drugs for target identification and drug repurposing

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Growth Hormone Secretagogue Receptor Type 1 (GH Releasing Peptide Receptor or Ghrelin Receptor or GHSR) development landscape

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Companies mentioned

Aeterna Zentaris Inc

Allergan Plc

AstraZeneca Plc

Extend Biosciences Inc

Helsinn Group

Lumos Pharma Inc

Millendo Therapeutics Inc

Oxeia Biopharmaceuticals Inc

Pfizer Inc

RaQualia Pharma Inc

TheraSource LLC

Zeria Pharmaceutical Co Ltd

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Growth Hormone Secretagogue Receptor Type 1 (GH Releasing Peptide Receptor or Ghrelin Receptor or GHSR) - Overview

Growth Hormone Secretagogue Receptor Type 1 (GH Releasing Peptide Receptor or Ghrelin Receptor or GHSR) - Therapeutics Development

Products under Development by Stage of Development

Products under Development by Therapy Area

Products under Development by Indication

Products under Development by Companies

Products under Development by Universities/Institutes

Growth Hormone Secretagogue Receptor Type 1 (GH Releasing Peptide Receptor or Ghrelin Receptor or GHSR) - Therapeutics Assessment

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Growth Hormone Secretagogue Receptor Type 1 (GH Releasing Peptide Receptor or Ghrelin Receptor or GHSR) - Companies Involved in Therapeutics Development

Aeterna Zentaris Inc

Allergan Plc

AstraZeneca Plc

Extend Biosciences Inc

Helsinn Group

Lumos Pharma Inc

Millendo Therapeutics Inc

Oxeia Biopharmaceuticals Inc

Pfizer Inc

RaQualia Pharma Inc

TheraSource LLC

Zeria Pharmaceutical Co Ltd

Growth Hormone Secretagogue Receptor Type 1 (GH Releasing Peptide Receptor or Ghrelin Receptor or GHSR) - Drug Profiles

anamorelin hydrochloride - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

AZ-12861903 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

EXT-405 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

EXT-418 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

HM-03 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

HM-04 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ibutamoren mesylate - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

livoletide - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

macimorelin acetate - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

OXE-103 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Peptide to Agonize GHSR for Acute Ischemic Stroke, Acute Radiation Syndrome and Sepsis - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

PF-05190457 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

relamorelin - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

RQ-00433412 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Antagonize Ghrelin Receptor for Obesity - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Agonize GHSR for Cachexia - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Synthetic Peptide to Modulate GHSR for Chronic Kidney Disease - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Z-505 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Growth Hormone Secretagogue Receptor Type 1 (GH Releasing Peptide Receptor or Ghrelin Receptor or GHSR) - Dormant Products

Growth Hormone Secretagogue Receptor Type 1 (GH Releasing Peptide Receptor or Ghrelin Receptor or GHSR) - Discontinued Products

Growth Hormone Secretagogue Receptor Type 1 (GH Releasing Peptide Receptor or Ghrelin Receptor or GHSR) - Product Development Milestones

Featured News & Press Releases

Apr 07, 2020: Aeterna Zentaris announces EMA decision to accept a modification to an agreed pediatric investigation plan for macimorelin

Apr 06, 2020: Millendo Therapeutics announces topline results for pivotal phase 2b study of Livoletide in patients with Prader-Willi Syndrome (PWS)

Apr 06, 2020: Aeterna Zentaris announces positive results in dose-finding pediatric study of macimorelin

Mar 12, 2020: Aeterna Zentaris announces settlement of previously disclosed class-action lawsuit

Feb 12, 2020: Aeterna Zentaris to present at Noble Capital Markets' 16th Annual Investor Conference

Jan 28, 2020: Aeterna Zentaris announces completion of patient recruitment in dose-finding pediatric study of Macimorelin

Dec 18, 2019: Aeterna Zentaris announces publication of GHD Management Guidelines

Nov 14, 2019: Millendo closes enrolment for first part of livoletide’s ZEPHYR trial

Nov 07, 2019: Millendo Therapeutics to Host Prader-Willi Syndrome (PWS) Breakfast Symposium on Thursday, November 14, 2019

Sep 26, 2019: Millendo Therapeutics to present at Prader-Willi Syndrome Conferences

Aug 01, 2019: UAB and Children's of Alabama to investigate new treatment for patients with Prader-Willi syndrome

May 17, 2019: Allergan expands PLEDGE Clinical Research Program in Diabetic Gastroparesis

May 08, 2019: Millendo Therapeutics announces 21st European Congress of Endocrinology 2019 presentations on Livoletide for Prader-Willi syndrome

Mar 19, 2019: Millendo Therapeutics initiates pivotal Phase 2b/3 clinical study of livoletide for the treatment of Prader-Willi Syndrome

Mar 14, 2019: Millendo Therapeutics announces ENDO 2019 presentation on livoletide for Prader-Willi Syndrome

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

List of Tables

Number of Products under Development by Stage of Development, H1 2020

Number of Products under Development by Therapy Areas, H1 2020

Number of Products under Development by Indication, H1 2020

Number of Products under Development by Companies, H1 2020

Products under Development by Companies, H1 2020

Products under Development by Companies, H1 2020 (Contd..1), H1 2020

Number of Products under Investigation by Universities/Institutes, H1 2020

Products under Investigation by Universities/Institutes, H1 2020

Number of Products by Stage and Mechanism of Actions, H1 2020

Number of Products by Stage and Route of Administration, H1 2020

Number of Products by Stage and Molecule Type, H1 2020

Pipeline by Aeterna Zentaris Inc, H1 2020

Pipeline by Allergan Plc, H1 2020

Pipeline by AstraZeneca Plc, H1 2020

Pipeline by Extend Biosciences Inc, H1 2020

Pipeline by Helsinn Group, H1 2020

Pipeline by Lumos Pharma Inc, H1 2020

Pipeline by Millendo Therapeutics Inc, H1 2020

Pipeline by Oxeia Biopharmaceuticals Inc, H1 2020

Pipeline by Pfizer Inc, H1 2020

Pipeline by RaQualia Pharma Inc, H1 2020

Pipeline by TheraSource LLC, H1 2020

Pipeline by Zeria Pharmaceutical Co Ltd, H1 2020

Dormant Products, H1 2020

Dormant Products, H1 2020 (Contd..1), H1 2020

Dormant Products, H1 2020 (Contd..2), H1 2020

Discontinued Products, H1 2020

List of Figures

List of Figures

Number of Products under Development by Stage of Development, H1 2020

Number of Products under Development by Therapy Areas, H1 2020

Number of Products under Development by Top 10 Indications, H1 2020

Number of Products by Mechanism of Actions, H1 2020

Number of Products by Stage and Mechanism of Actions, H1 2020

Number of Products by Routes of Administration, H1 2020

Number of Products by Stage and Routes of Administration, H1 2020

Number of Products by Molecule Types, H1 2020

Number of Products by Stage and Top 10 Molecule Types, H1 2020

    Pricing

Discounts available for multiple report purchases.

reportstore@globalmarketsdirect.com
+44 (0) 161 359 5414

Saved reports